At first, scientists had no idea what might cause Alzheimer’s disease and had no underlying protein or pathway to target with treatments. Then came…
Since their discovery in the 1960s, stem cells have captivated our curiosity. Unlike other cells in the body, stem cells are changeable — they…
Anti-amyloid drugs like Leqembi and Kisunla are among the first FDA-approved treatments for early-stage Alzheimer’s disease. But these breakthroughs come with a tradeoff: Up…
More than a decade ago, Alzheimer’s vaccines appeared in clinical trials — but failed. Now several companies are gearing up to test the next…
Scientists developed new brain cells to replace those lost in Parkinson’s. Early trials showed they’re safe — now, larger human trials are on the…
People with Down syndrome have a 9/10 chance of developing early-onset Alzheimer’s — a reality tied to genetics. This genetic condition also makes this…
In July 2024, European regulators rejected Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. By November, they had changed their minds. Now, the…
Your genetics could make you more vulnerable to the side effects of the new class of Alzheimer’s drugs. Carrying two copies of the ApoE4…
When ancient Greek soldiers laid their mythical siege upon the city of Troy, they struggled to break through the city’s impenetrable walls. To finally…
Years before any symptoms of Alzheimer’s appear, beta-amyloid and tau proteins misfold, tangle, and aggregate inside the brain. While many people may develop beta-amyloid…
Treatment with a powerful magnet is one of the newest experimental therapies being used to try to turn back the clock on Alzheimer’s disease….
Before Americans become eligible for Medicare at 65, they often rely on private insurance. But for people who start showing signs of Alzheimer’s in…
Loneliness, heart disease, diabetes, and mental health conditions all put older Americans at a higher risk of developing cognitive decline and Alzheimer’s disease. Looking…
Anti-amyloid drugs like Leqembi and Kisunla are on the market for treating early Alzheimer’s disease, but they are expensive, difficult to access, and only…
In November of last year, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase…